Whole-exome and Targeted Gene Sequencing of Gallbladder Carcinoma Identifies Recurrent Mutations in the ErbB Pathway
Maolan Li,Zhou Zhang,Xiaoguang Li,Junyi Ye,Xiangsong Wu,Zhujun Tan,Chang Liu,Baiyong Shen,Xu-An Wang,Wenguang Wu,Daizhan Zhou,Di Zhang,Ting Wang,Bingya Liu,Kai Qu,Qichen Ding,Hao Weng,Qian Ding,Jiasheng Mu,Yijun Shu,Runfa Bao,Yang Cao,Peizhan Chen,Tianyu Liu,Lin Jiang,Yunping Hu,Ping Dong,Jun Gu,Wei Lu,Weibin Shi,Jianhua Lu,Wei Gong,Zhaohui Tang,Yong Zhang,Xuefeng Wang,Y Eugene Chin,Xiaoling Weng,Hong Zhang,Wei Tang,Yonglan Zheng,Lin He,Hui Wang,Yun Liu,Yingbin Liu
DOI: https://doi.org/10.1038/ng.3030
IF: 30.8
2014-01-01
Nature Genetics
Abstract:Individuals with gallbladder carcinoma (GBC), the most aggressive malignancy of the biliary tract, have a poor prognosis. Here we report the identification of somatic mutations for GBC in 57 tumor-normal pairs through a combination of exome sequencing and ultra-deep sequencing of cancer-related genes. The mutation pattern is defined by a dominant prevalence of C>T mutations at TCN sites. Genes with a significant frequency (false discovery rate (FDR)<0.05) of non-silent mutations include TP53 (47.1%), KRAS (7.8%) and ERBB3 (11.8%). Moreover, ErbB signaling (including EGFR, ERBB2, ERBB3, ERBB4 and their downstream genes) is the most extensively mutated pathway, affecting 36.8% (21/57) of the GBC samples. Multivariate analyses further show that cases with ErbB pathway mutations have a worse outcome (P=0.001). These findings provide insight into the somatic mutational landscape in GBC and highlight the key role of the ErbB signaling pathway in GBC pathogenesis.